MESANTOIN
LOE ApproachingNDAORALTABLET
Approved
Oct 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESANTOIN (mephenytoin) is an oral small-molecule anticonvulsant approved in 1946 for the treatment of epilepsy. It functions as a hydantoin-class anticonvulsant, stabilizing neuronal membranes to prevent seizure activity. This legacy product represents an early-generation antiepileptic now facing significant market pressure from newer therapeutic options.
LOE Approaching
Declining market position with 30% competitive pressure signals contraction; commercial teams likely focused on margin preservation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Positions linked to MESANTOIN reflect legacy product management in a declining market with minimal career growth opportunities. Professionals joining this team should expect focus on regulatory compliance, cost management, and transition planning rather than brand expansion or innovation.
Brand Manager (Legacy Products)Regulatory Affairs Specialist
Worked on MESANTOIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.